Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$0.23 - $0.46 $8,068 - $16,137
-35,082 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$0.3 - $0.61 $68,169 - $138,611
-227,232 Reduced 86.63%
35,082 $16,000
Q4 2021

Feb 14, 2022

BUY
$0.55 - $1.04 $95,697 - $180,955
173,996 Added 197.01%
262,314 $144,000
Q3 2021

Nov 09, 2021

SELL
$1.06 - $1.52 $14,078 - $20,188
-13,282 Reduced 13.07%
88,318 $93,000
Q2 2021

Aug 13, 2021

SELL
$1.22 - $1.65 $184,962 - $250,154
-151,609 Reduced 59.88%
101,600 $153,000
Q1 2021

May 13, 2021

BUY
$1.18 - $2.62 $230,164 - $511,044
195,055 Added 335.41%
253,209 $389,000
Q4 2020

Feb 11, 2021

BUY
$1.05 - $2.24 $257 - $548
245 Added 0.42%
58,154 $61,000
Q3 2020

Nov 12, 2020

BUY
$1.7 - $6.41 $20,318 - $76,612
11,952 Added 26.01%
57,909 $118,000
Q2 2020

Aug 12, 2020

BUY
$0.87 - $2.46 $39,982 - $113,054
45,957 New
45,957 $103,000
Q1 2020

May 13, 2020

SELL
$0.22 - $2.45 $6,609 - $73,600
-30,041 Closed
0 $0
Q4 2019

Feb 10, 2020

BUY
$0.11 - $0.58 $3,304 - $17,423
30,041 New
30,041 $7,000

About iBio, Inc.


  • Ticker IBIO
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,006,580
  • Market Cap $24M
  • Description
  • iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for t...
More about IBIO
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.